Ngā hua rapu - Hagop M. Kantarjian

Whakamahine hua
  1. 1
    Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring

    Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring mā Elias Jabbour, Hagop M. Kantarjian

    I whakaputaina 2018
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring

    Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring mā Elias Jabbour, Hagop M. Kantarjian

    I whakaputaina 2020
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    Core binding factor acute myelogenous leukemia-2021 treatment algorithm

    Core binding factor acute myelogenous leukemia-2021 treatment algorithm mā Gautam Borthakur, Hagop M. Kantarjian

    I whakaputaina 2021
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    Moving toward individualized target-based therapies in acute myeloid leukemia

    Moving toward individualized target-based therapies in acute myeloid leukemia mā Alexandre Bazinet, Hagop M. Kantarjian

    I whakaputaina 2022
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring

    Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring mā Elias Jabbour, Hagop M. Kantarjian

    I whakaputaina 2024
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    How I treat newly diagnosed chronic phase CML

    How I treat newly diagnosed chronic phase CML mā Jorge E. Cortés, Hagop M. Kantarjian

    I whakaputaina 2012
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    Impact of Cancer Research Bureaucracy on Innovation, Costs, and Patient Care

    Impact of Cancer Research Bureaucracy on Innovation, Costs, and Patient Care mā David P. Steensma, Hagop M. Kantarjian

    I whakaputaina 2014
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors

    Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors mā Fadi G. Haddad, Hagop M. Kantarjian

    I whakaputaina 2024
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    The biology and therapy of adult acute lymphoblastic leukemia

    The biology and therapy of adult acute lymphoblastic leukemia mā Stefan Faderl, Sima Jeha, Hagop M. Kantarjian

    I whakaputaina 2003
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  10. 10
    Targeting DNA Methylation

    Targeting DNA Methylation mā Jean–Pierre J. Issa, Hagop M. Kantarjian

    I whakaputaina 2009
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  11. 11
    Acute promyelocytic leukemia current treatment algorithms

    Acute promyelocytic leukemia current treatment algorithms mā Musa Yılmaz, Hagop M. Kantarjian, Farhad Ravandi

    I whakaputaina 2021
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  12. 12
    Adult Acute Lymphoblastic Leukemia

    Adult Acute Lymphoblastic Leukemia mā Shilpa Paul, Hagop M. Kantarjian, Elias Jabbour

    I whakaputaina 2016
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  13. 13
    Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

    Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy mā Xuelin Huang, Jorge E. Cortés, Hagop M. Kantarjian

    I whakaputaina 2012
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  14. 14
    Use of Second- and Third-Generation Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia: An Evolving Treatment Paradigm

    Use of Second- and Third-Generation Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia: An Evolving Treatment Paradigm mā Elias Jabbour, Hagop M. Kantarjian, Jorge E. Cortés

    I whakaputaina 2015
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  15. 15
    Failure of Hypomethylating Agent–Based Therapy in Myelodysplastic Syndromes

    Failure of Hypomethylating Agent–Based Therapy in Myelodysplastic Syndromes mā Tapan M. Kadia, Elias Jabbour, Hagop M. Kantarjian

    I whakaputaina 2011
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  16. 16
    Resistance to Tyrosine Kinase Inhibition Therapy for Chronic Myelogenous Leukemia: A Clinical Perspective and Emerging Treatment Options

    Resistance to Tyrosine Kinase Inhibition Therapy for Chronic Myelogenous Leukemia: A Clinical Perspective and Emerging Treatment Options mā Elias Jabbour, Jorge E. Cortés, Hagop M. Kantarjian

    I whakaputaina 2013
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  17. 17
    Long‐term outcomes in the second‐line treatment of chronic myeloid leukemia

    Long‐term outcomes in the second‐line treatment of chronic myeloid leukemia mā Elias Jabbour, Jorge E. Cortés, Hagop M. Kantarjian

    I whakaputaina 2010
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  18. 18
    Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015

    Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015 mā Philip A. Thompson, Hagop M. Kantarjian, Jorge E. Cortés

    I whakaputaina 2015
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  19. 19
    Discontinuation of imatinib therapy after achieving a molecular response

    Discontinuation of imatinib therapy after achieving a molecular response mā Jorge E. Cortés, Susan O’Brien, Hagop M. Kantarjian

    I whakaputaina 2004
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Carta
    Tiaki ki tētahi rārangi
    I tiakina i:
  20. 20
    Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes

    Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes mā Elias Jabbour, Hagop M. Kantarjian, Charles Koller, Alì Taher

    I whakaputaina 2008
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: